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Background: At the population level, asthma has been associated with chronic systemic inflam-
mation as well as adverse cardiovascular outcomes.
Objectives: The aim of this study was to investigate peripheral vascular hemodynamic variables
of arterial stiffness (AS) and their relationship to pulmonary function tests in asthmatic patients.
Methods: Young asthmatic patients from the tertiary center for pulmonary diseases at the Barzi-
lai Medical Center underwent pulmonary function evaluation and non-invasive radial artery
hemodynamic profiling, pre- and post-exercise. Results were compared to age matched, non-
asthmatic controls.
Results: 23 young asthmatics and 41 controls, completed all evaluation points. Pulmonary flow
parameters were significantly reduced in the asthma group at all points. There were no differ-
ences between groups in BMI, blood pressure, pulse rate or measurements of AS at baseline or
after bronchodilation. The % predicted forced expiratory volume in the first second at baseline
(FEV1%) in asthmatics was positively correlated with the small arteries elasticity index (SAEI)
and negatively correlated with the systemic vascular resistance (SVR) in these patients. These
correlations were not observed in non-asthmatic controls. In multifactorial regression FEV1 re-
mained themajor factor associatedwithmeasurements of AS in asthmatic patients,while gender
was the only significant factor in non-asthmatic controls.iance; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; CET, estimated
cardiac index; ECO, estimated cardiac output; ECT, exercise challenge tests; ESV, estimated stroke
e index; FEV1, forced expiratory volume in the first second; FEV1%, % predicted forced expiratory
artery elasticity index; MAP, mean arterial BP; Mch, methacholine; MCTs, methacholine challenge
PP, pulse pressure; PR, pulse rate; SAEI, small artery elasticity index; SBP, systolic blood pressure;
I, total vascular impedance.
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198 Z. Weiler et al.Conclusions: Significant correlations between measurements of AS and FEV1 in young asth-
matics, suggest the presence of a common systemic, most likely inflammatory pathway involving
both the cardiovascular and respiratory systems.
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Bronchial asthma is a chronic inflammatory disease char-
acterized by airway inflammation and bronchial hyper
responsiveness together with recurrent bouts of cough,
wheezing, shortness of breath, chest tightness and revers-
ible airways obstruction.1 The systemic nature of the
chronic inflammation in asthma was emphasized recently
by studies, showing an increased risk of asthma associated
with the higher percentiles of C-reactive protein (CRP) in
serum,2e5 correlation between severe asthma and highly
sensitive CRP,6 high serum levels of tumor necrosis factor-
alpha and interleukin-8 in severe asthma,7 multiple
markers of chronic systemic inflammation associated with
asthma and the risk of atherogenesis8 and positive epide-
miological associations of asthma with the risk for
myocardial infarction and stroke in some populations.9e11
Chronic inflammation has also been increasingly associ-
ated with atherosclerosis12 endothelial dysfunction13 and
arterial stiffness (AS)14 and these in turn with adverse
cardiovascular events15 and common inflammatory
pathways.16,17
Measurements of peripheral arterial stiffness (AS)
correlate well with atherosclerotic cardiovascular disease
(ASCVD) and adverse cardiovascular outcomes.18e22 Non-
invasive techniques measuring arterial stiffness and
vascular resistance of large and small vessels are increas-
ingly used as surrogate markers for early atherosclerosis
and the risk of cardiovascular events.19,23,24
Previous studies25,26 have shown that mean aortic pulse
wave velocity as well as inflammatory markers and
augmentation index, were significantly greater in COPD
patients compared to healthy control subjects. The authors
concluded that the increased arterial stiffness is related to
the severity of the airflow obstruction in COPD. Similar
data however have not been published in asthmatic
patients.
Pulmonary function tests obtained by spirometry are the
golden standard for the diagnosis and evaluation of asthma
and loss of pulmonary function constitutes a major hallmark
of the progression of asthma in adults.1
In view of the above we aimed to investigate the
correlations of peripheral vascular hemodynamic variables




Otherwise healthy, young stable asthmatic patients, less
than 40 years of age, from the tertiary center for pulmo-
nary diseases at the Barzilai medical center were offered
the extensive evaluation as part of a routine follow-up.Patients were excluded if they had sustained an acute
asthma exacerbation requiring oral steroids and/or
unscheduled emergency room visit and/or hospitalization
during the 3 months preceding their visit. Additional
exclusion criteria included smoking of more than 1 pack
a day. The study was approved by the hospital’s internal
review board and all patients signed a written informed
consent. None of our patients had any history of cardio-
vascular or other significant chronic disease other than
bronchial asthma. Patients underwent pulmonary function
evaluation and non-invasive radial hemodynamic profiling,
pre- and post-exercise testing and 15 min after an inhaled
bronchodilator. In our case control study design, each
individual patient in the study group was age and sex
matched to 2 non-asthmatic controls. Allergic testing was
not performed as part of the routine evaluation of the study
or control groups.
Pulmonary function tests (PFT)
Pulmonary function tests were performed using a JAEGER
MasterLab Spirometer by an experienced technician and
according to the published ATS criteria27 and in comparison
to Knudson’s predicted values.28 After having undergone an
initial pre- and post-bronchodilator pulmonary function
tests (PFTs), all study as well as control group patients
underwent arterial compliance measurements at baseline,
after a standardized exercise test and again 15 min after an
inhaled bronchodilator.
Exercise challenge test
Exercise challenge tests (ECTs), were performed on
a treadmill to 85% of predicted maximum heart rate for
6e8 min and PFTs performed before and after exercise at
5 min intervals for 15 min according to ATS published
guidelines.29 A decrease of 12 percent in FEV1 in
comparison to baseline FEV1 was considered a positive
test.
Methacholine test
The methacholine (Mch) bronchoprovocation challenge test
was performed using a series of Mch chloride solutions
ranging from the most dilute concentration of 0.06 mg/ml
of Mch, to a concentration of 16 mg/ml at two-fold incre-
mental concentration intervals.29
The diluted doses were administered by nebulizer and
after each concentration inhalation of the aerosol, the
FEV1 was measured at 1, 3, 5 and 10 min. The inhalation of
increasing Mch concentrations continued until a 20 percent
drop in FEV1 was observed or until the maximal concen-
tration was inhaled (16 mg/ml). The dose which provoked
a 20 percent drop in FEV1 was referred to as the PC20. The
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was achieved with a concentration of 8 mg/ml Mch or less
or if PC20 was reached at a maximal dose of 16 mg/ml
where the physical findings or clinical story were
significant.
Asthma diagnosis
A diagnosis of asthma was made according to GINA asthma
diagnosis guidelines (Global Initiative for Asthma, Global
Strategy for Asthma Diagnosis and Prevention, Global
Initiative for Asthma, 2004). All study group patients had
established stable asthma according to clinical criteria and
proven reversibility of FEV1 on PFTs and/or positive exer-
cise challenge test, and/or a positive methacholine chal-
lenge test while in the control group, exclusion of asthma
diagnosis was based on negativity of the same pulmonary
functions and challenge tests.
Arterial stiffness measurement
Arterial stiffness/compliance measurements were per-
formed in a quiet, temperature controlled laboratory. The
patients had been fasting for at least 3 h and none had
consumed caffeine containing beverages or alcohol.
Radial artery waveforms were recorded for 30 s for each
subject in the supine position just before, immediately
after exercise testing as well as 15 min after 2 puffs of an
inhaled beta-agonist bronchodilator. The pressure trans-
ducer amplifier system was connected to a specially
designed device (Model CR-2000, Hypertension diagnostics,
Inc, Eagen, MN). The passive transient response of the
arterial vasculature to the initial loading conditions was
determined by analyzing the diastolic portion of the pres-
sure pulse waveform. This technique which has been used
and described extensively,21 was used with the simple
non-invasive radial pulse wave recording and a computer
analysis of the diastolic decay. This provided separate
assessment of the large artery (capacitive or conduit)
compliance (C1) and small artery (reflective or oscillatory)
compliance (C2). Both artery types were measured because
studies have demonstrated an age-dependent decline in
both C1 and C2 parameters, reflecting structural or func-
tional changes in the large conduit arteries, as well as in
the smaller reflective sites.
Systemic vascular resistance (SVR) was calculated as the
mean arterial pressure (MAP) divided by cardiac output.
The MAP was derived from waveform analysis, integrating
the area under the curve and calculating the mean area of
recording during 30 s.
Statistical analysis
Continuous variables are expressed as mean standard
deviation (SD) and were analyzed by the ANOVA test or
paired t test. Spearman non-parametric correlation analysis
was chosen to estimate correlations between FEV1% and
measures of arterial stiffness/compliance, because of the
relatively small number of measurements. A p-value <0.05
was considered statistically significant. Multivariate
regression analysis with the forward conditional model wasused to elicit factors of significance for the various
measurements of arterial stiffness. All statistical tests were
performed using the SPSS 15.0 software for Windows, SPSS
Inc., Chicago, USA.
Results
64 patients from the outpatient pulmonary clinic of the
Barzilai Medical Center in Ashkelon, were included in the
study. 23 (15 males and 8 females) with established stable
asthma, served as the study group while 41 patients (22
males and 19 females) in whom asthma diagnosis was
excluded by both pulmonary function and provocation
tests, some served as a control group (Table 1) The mean
age range of the study group was 23 years with a mean body
mass index (BMI) of 22 while the control’s group mean age
and BMI were 24 and 23 respectively. There were no
statistically significant differences in the reported smoking
history, however the non-asthmatic smokers reported
mildly heavier use.
All study group patients had established stable asthma
according to clinical criteria and proven reversibility of
FEV1 on PFTs and/or positive exercise challenge test, and/
or a positive methacholine challenge test while in the
control group, exclusion of asthma diagnosis was based on
negativity of the same pulmonary functions or challenge
tests. At the time of initial study evaluation 14 (61%) of
asthmatics were using short acting beta-agonists (SABA)
compared to 10 (24%) among controls, however none had
used their SABA medications at least 6 h before tests were
administered. 9 asthma patients (39%) were using inhaled
corticosteroids at a dose of less than 400 mcg of Budesonide
(or equivalent) per day compared to 3 (7%) among controls,
and 2 (9%), were on a leukotriene receptor antagonists
(Montelukast) compared to none among the control group.
At all measured points, pulmonary function tests as
reflected by the mean % predicted FEV1 (FEV1%) were
significantly reduced when compared to age matched non-
asthmatic controls e 77.9% vs 99.7%, p< 0.001 at baseline,
67% vs 98.6%, p< 0.001 after the exercise test and 83.2% vs
99.9%, p< 0.001, after bronchodilators (Table 1).
There were no differences in blood pressure, pulse rate
or measurements of small or large vessel elasticity/stiff-
ness between asthmatics and non-asthmatic controls at
baseline (Table 1).
A good correlation was observed between the FEV1% in
asthmatic patients at rest (baseline) and the estimated
cardiac output (ECO) at rest (Spearman correlation coeffi-
cient rhoZ 0.678, p< 0.001), as well as the small arteries
elasticity index (SAEI) at rest (rhoZ 0.418, p< 0.05),
Fig. 1. Conversely a negative correlation was observed
between baseline FEV1% and the systemic vascular resis-
tance (SVR) as well as the total vascular impedance (TVI) at
rest, (Spearman correlation coefficients rhoZ0.429,
p< 0.05 and rhoZ0.489, p< 0.05 respectively), Fig. 2.
Baseline % predicted FEV1 (FEV1%) in our asthmatic
patients correlated well with systolic blood pressure
(spearman correlation coefficients rhoZ 0.560, p< 0.005),
mean arterial blood pressure (spearman correlation coef-
ficients rhoZ 0.419, p< 0.05), pulse pressure (spearman
correlation coefficients rhoZ 0.549, p< 0.01), and pulse
rate (spearman correlation coefficients rhoZ 0.484,
Table 1 Clinical characteristics of asthmatic patients and non-asthmatic controls.
Asthma (nZ 23) Controls (nZ 41) p
Age mean (range) 23 (18e37) 24 (19e39) NS
BMI mean (range) 22 (17e28) 23 (18e30) NS




FEV1% baseline 77.9% (52.3e106) 99.7% (79.3e115.7) <0.001
FEV1% post ECT 67% (42.9e94.1) 98.6% (77.6e123.2) <0.001
FEV1% postBD 83.2% (63.6e106.6) 99.9% (82.5e130.7) <0.001
sBP at baseline mmHg mean (95% CI) 114.6 (110.9e118.2) 114.9 (111.6e118.2) NS
dBP at baseline mmHg mean (95% CI) 61.7 (58.5e64.8) 64.7 (61.5e67.8) NS
PP at baseline mmHg mean (95% CI) 52.9 (50.5e55.4) 53.4 (50.0e56.8) NS
PR at baseline
beats/min mean (95% CI)
68.4 (64.6e72.1) 68.3 (65.4e71.3) NS
LAEI mean (95% CI) 14.4 (12.8e16.0) 15.3 (14.0e16.5) NS
SAEI mean (95% CI) 7.4 (6.6e8.2) 7.0 (6.3e7.6) NS
NS e not significant, FEV1% e percent of predicted forced expiratory volume in the 1st second, ECT e exercise challenge test, BD e
bronchodilator, sBP e systolic blood pressure, dBP e diastolic blood pressure, PP e pulse pressure, PR e pulse rate, LAEI e large arteries
elasticity index, SAEI e small arteries elasticity index.
a At a dose of less than 400 mcg budesonide (or equivalent) or less than 250 mcg fluticasone or equivalent or Montelukast at a dose of
10 mg per day.
200 Z. Weiler et al.p< 0.05), measured after exercise (as detailed in text) and
again after rescue bronchodilation (similar correlation
coefficients and significance values).
FEV1% after bronchodilator (postBD) rescue also corre-
lated positively with postBD SAEI in asthmatic patients,
(spearman correlation coefficients rhoZ 0.434, p< 0.05),
Fig. 3.
In the control group, no correlation was seen between
measurements of pulmonary function and arterial stiffness/
compliance at any time point.Figure 1 FEV1% at baseline correlates positively with small
arteries elasticity index in asthmatic patients. SAEI e small
arteries elasticity index, FEV1% e forced expiratory volume in
the first second. Expressed as a percentage of the predicted
FEV1 for gender, height and age, R e spearman coefficient
(rho), p e level of significance.In multivariate linear regression analysis, evaluating the
impact of gender, BMI. Smoking status and baseline FEV1%
are elements of large and small vessel elasticity, only
gender, but not smoking status or FEV1% was a significant
factor in the measurements of small arteries elasticity
index (SAEI) at rest in non-asthmatic controls.
In asthmatic patients on the other hand, the same
multivariate analysis showed that only FEV1% remained
positively correlated with the small arteries elasticity index
at rest (rhoZ 0.401, p< 0.05) and after rescue broncho-
dilation (rhoZ 0.455, p< 0.05).
Discussion
Since our goal was to reveal a possible correlation between
asthma as a chronic inflammatory airway disease and early-
on vascular changes, we based the study on a young pop-
ulation of otherwise healthy patients, less than 40 years of
age, in whom the risk of significant atherosclerotic
cardiovascular disease was very low.
All patients included in the study, subjects as well as
controls were referred to the pulmonary unit because of
clinical chest complaints, for whom also received bron-
chodilator and anti-inflammatory medication such as
inhaled corticosteroids or leukotriene antagonists.
Following an extensive evaluation including, pulmonary
functions, exercise and pharmacological challenge testing,
subject patients had a confirmed diagnosis of asthma
according to accepted ATS criteria, while control patients
tested negative to all the above mentioned tests. Never-
theless some of the control patients at recruitment were
taking anti-asthmatic medication as detailed in the Results
section.
Our study shows a positive correlation between periph-
eral arterial stiffness measurements and the degree of
airway limitation in young asthmatic patients. This is
Figure 2 FEV1% at baseline correlates negatively with
systemic vascular resistance in asthmatic patients. SVR e
systemic vascular resistance, FEV1% e forced expiratory
volume in the first second. Expressed as a percentage of the
predicted FEV1 for gender, height and age, R e spearman
coefficient (rho), p e level of significance.
Figure 3 FEV1% after bronchodilator (postBD) rescue corre-
lates positively with postBD SAEI in asthmatic patients. SAEI e
small arteries elasticity index (measured after rescue bron-
chodilation), FEV1% e forced expiratory volume in the first
second. Expressed as a percentage of the predicted FEV1 for
gender, height and age (measured after rescue bronchodila-
tion), R e spearman coefficient (rho), p e level of significance.
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baseline FEV1% values and ECO, SVR and TVI in asthmatics
but not in controls, and significant correlations between %
predicted FEV1 and mostly small arteries stiffness at
baseline and postBD again in asthmatics but not in controls.
FEV1% at rest and after response to bronchodilation are
a generally accepted surrogate marker of asthma severity.
In prospective studies in young children, FEV1 at rest and
post-bronchodilator FEV1 were reduced in children with
severe atopic asthma and correlated well with asthma
severity, and airway inflammation.30 The correlation of
baseline FEV1% with indexes of arterial stiffness/compli-
ance observed in our study in patients with asthma but not
in non-asthmatic controls suggests that a common inflam-
matory pathway at work in the asthmatic airways of indi-
vidual patients, is associated with chronic changes in the
systemic cardiovascular system. This finding may be part of
the underlying mechanism linking longstanding asthma and
asthma severity with increased risk of CVS adverse
outcomes, myocardial infarction and/or strokes.9,10,31,32
Another readily available explanation may be that
common mechanisms in the pathway of endothelial
changes/arterial stiffness development and asthma devel-
opment may be at work in asthmatic individuals. This was
demonstrated in our study by the positive correlation
between baseline (resting) as well as post exercise FEV1
and SAEI as well as LAEI. Such pathways may involve smooth
muscle reactivity33 and proliferation34 or alternatively
genetic changes in leukotriene production pathways and
function. Yet another possibility is that the use of certain
drugs such as beta-agonists may be the link between
asthma and adverse CVS outcomes.35,36 However, most of
our patients (61%) received short acting bronchodilators
(SABAs) as did 24% of controls, and all patients as well as
controls had not used this medication at least 6 h before
testing, therefore our data does not support beta-agonists
as an immediate explanation for the differences observed
between groups.Whatever the molecular basis of this correlation, it
confirms at the individual level the population derived data of
increased risk of atherosclerotic cardiovascular disease in
patients with asthma and proposes that these risks may be
commensurate with the degree of airflow limitation as
measured by FEV1% in pulmonary function testing. The
systemic inflammation theory is strengthened by research
showing a decreased risk of ASCVD and death in asthmatic
patients taking anti-inflammatorymedications.37e39 Although
the correlation found between FEV1 and measures of periph-
eral arterial stiffness in asthmatics is striking, the absolute
hemodynamicmeasurements in this young healthy population
were not significantly different from non-asthmatic controls.
This finding is diametrically opposed to the findings of Sabit
and Boussuges in COPD patients,25,26 most likely secondary to
our choosing of young, otherwise healthy patients, lacking
significant cardiovascular disease for this study.
In the past few years increasing awareness of the limita-
tion of preventative therapy has changed our therapeutic
approach in mild and moderate asthmatics towards symp-
toms oriented therapy, whereby control of untoward symp-
toms is the primary outcome. This change has been
advocatedmainly because of the lack of data supporting any
long-term effects of anti-inflammatory medication on the
outcome of airway disease. However, our study implies that
long term cardiovascular changes may also be part of the
associated morbidity in asthmatics and additional data
published and cited above would seem to suggest that these
may indeed respond to long-term anti-inflammatory medi-
cation. If supported by larger and long-term prospective
data, using peripheral arterial stiffness as an outcome of
asthma follow-up and treatment, this data may change the
recommended policy to one of continuous anti-inflammatory
treatment similar to what is now advocated for other ASCVD
risk factors such as hypertension and hypercholesterolemia.
The limitations of this study are clear. Only a relatively
small number of individuals participated. We have also not
shown a clear correlation with individual markers of
202 Z. Weiler et al.systemic inflammation. Previous studies looking at markers
of inflammation in asthmatic patients, have used a large
cross sectional population design to show increased risk of
asthma in patients on the higher CRP quartiles Since the
documented absolute changes were small and they repre-
sent only surrogate markers of inflammation we decided
not to include these measurements in our study.
However as all cross sectional studies may be, ours is
indeed able to generate a working hypothesis e and that is
the systemic inflammation associated with bronchial asthma
has measurable cardiovascular outcomes that ultimately
may increase an individual’s risk of myocardial infarction
and/or stroke. A larger prospective, long-term study is
needed to validate the results and answer the question of
which anti-inflammatory treatment may best influence the
vascular systemic changes associated with asthma.
Conclusion
The correlation between measurements of arterial
compliance and pulmonary function tests in otherwise
healthy young asthmatics suggests that the chronic airway
inflammation characteristic of asthma may have severe
additional effects in the systemic vasculature, and these
may require prospective monitoring and treatment.
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